TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 3145297
Drug: Vehicle (control
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle (control treatment)
Study: 30661697
Drug: Pomegranate juice
Normalized name: pomegranate juice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pomegranate juice (PJ) 200 ml/day for 6 weeks
Study: 29055956
Drug: Higher daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher daily salt intake (2.0 g/day higher compared with normal weight individuals) after multivariable adjustment, 95% CI, 1.2‐2.8 g/day, P < 0.001
Study: 25315830
Drug: Quetiapine (386.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quetiapine (386.3 mg/day)
Study: 25315830
Drug: Risperidone (3.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risperidone (3.2 mg/day)
Study: 21574968
Drug: Sugammadex 16
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sugammadex 16 mg/kg (Study A)
Study: 21574968
Drug: Sugammadex 2
Normalized name: sugammadex 200 MG in 2 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sugammadex 2 mg/kg (Study B)
Study: 16965429
Drug: Methyl aminolaevulinate-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methyl aminolaevulinate-based photodynamic therapy (MAL-PDT) for actinic keratosis (AK)
Study: 16965429
Drug: Methyl aminolaevulinate-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methyl aminolaevulinate-based photodynamic therapy (MAL-PDT) for nodular basal cell carcinoma (BCC)
Study: 16965429
Drug: Methyl aminolaevulinate-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methyl aminolaevulinate-based photodynamic therapy (MAL-PDT) for superficial basal cell carcinoma (BCC)
Study: 7879632
Drug: Cognitive therapy
Normalized name: cognitive therapy software
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive therapy (various intervention sequences)
Study: 29998524
Drug: C1-inhibitor (C1-INH)
Normalized name: C1 INHIBITOR
DrugBank: Conestat alfa (DB09228)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: C1-inhibitor (C1-INH) subcutaneous (SC) administration, 40 IU/kg twice weekly
Study: 29998524
Drug: C1-inhibitor (C1-INH)
Normalized name: C1 INHIBITOR
DrugBank: Conestat alfa (DB09228)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: C1-inhibitor (C1-INH) subcutaneous (SC) administration, 60 IU/kg twice weekly
Study: 29998524
Drug: C1-inhibitor (C1-INH)
Normalized name: C1 INHIBITOR
DrugBank: Conestat alfa (DB09228)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: C1-inhibitor (C1-INH) intravenous (IV) administration, 1000 IU
Study: 26014092
Drug: Diclofenac patch
Normalized name: diclofenac Medicated Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diclofenac patch applied twice a day for 7 days
Study: 26014092
Drug: Placebo patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo patch applied twice a day for 7 days
Study: 24596084
Drug: Tonsillectomy combined
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tonsillectomy combined with steroid pulses
Study: 24596084
Drug: Steroid pulses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Steroid pulses alone
Study: 18215213
Drug: Topiramate 300
Normalized name: topiramate 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topiramate 300 mg/d
Study: 12365887
Drug: Ketoprofen administered
Normalized name: Ketoprofen
DrugBank: Ketoprofen (DB01009)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ketoprofen administered before surgery and regular doses after discharge for 72 hours
Study: 12365887
Drug: Ketoprofen administered
Normalized name: Ketoprofen
DrugBank: Ketoprofen (DB01009)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ketoprofen administered at discharge
Study: 12365887
Drug: Ketoprofen doses
Normalized name: Ketoprofen
DrugBank: Ketoprofen (DB01009)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ketoprofen doses after discharge
Study: 8135325
Drug: 6.7 mmol
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6.7 mmol (167 mg) magnesium aspartate
Study: 2572616
Drug: Azelastine hydrochloride,
Normalized name: Azelastine Hydrochloride, 0.05% ophthalmic solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azelastine hydrochloride, 8.8 mg
Study: 29098501
Drug: Intravenous carperitide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous carperitide (0.02 μg/kg/min) in addition to standard treatment
Study: 29098501
Drug: Matching standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching standard treatment
Study: 25336731
Drug: Inactivated A(H1N1)pdm09
Normalized name: poliovirus vaccine inactivated, type 1 (Mahoney)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inactivated A(H1N1)pdm09 vaccine
Study: 19549426
Drug: Olopatadine 0.6%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olopatadine 0.6% nasal spray (2 sprays/nostril b.i.d.)
Study: 19549426
Drug: Fluticasone propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fluticasone propionate 50 microg nasal spray (2 sprays/nostril q.d.)
Study: 19549426
Drug: Olopatadine 0.6%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olopatadine 0.6% nasal spray
Study: 19549426
Drug: Olopatadine 0.6%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olopatadine 0.6% nasal spray and Fluticasone propionate 50 microg nasal spray
Study: 19549426
Drug: Fluticasone propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fluticasone propionate 50 microg nasal spray
Study: 14530982
Drug: Power training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Power training (twice a week for 15 weeks)
Study: 8216567
Drug: naproxen sodium
Normalized name: Naproxen Sodium
DrugBank: Naproxen (DB00788)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: naproxen sodium 550 mg twice daily for 10 days
Study: 29483043
Drug: Everolimus (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Everolimus (10 mg/d)
Study: 27936233
Drug: Lopinavir-ritonavir (LPV-rtv)
Normalized name: lopinavir / ritonavir
DrugBank: Lopinavir (DB01601)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lopinavir-ritonavir (LPV-rtv) based ART with anti-malarial treatment
Study: 25429720
Drug: Remifentanil (0.15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil (0.15 μg(‐1)kgIBW(‐1) min(‐1))
Study: 25429720
Drug: Fentanyl (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl (200 to 500 μg as needed)
Study: 8472828
Drug: (+/‐)‐telenzepine (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: (+/‐)‐telenzepine (3 mg orally at 6 p.m. for 5 days)
Study: 27385377
Drug: Foley's catheter
Approvals — FDA: no, EMA: no, PMDA: no
Description: Foley's catheter or low-dose vaginal misoprostol alone
Study: 24932625
Drug: intralymphatic immunotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: intralymphatic immunotherapy (ILIT)
Study: 24932625
Drug: subcutaneous immunotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: subcutaneous immunotherapy (SCIT)
Study: 17652881
Drug: Intracoronary infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intracoronary infusion of non-expanded peripheral blood mononuclear cells (PBMNCs) within 5 days after PCI
Study: 17652881
Drug: Intracoronary infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intracoronary infusion of PBMNCs
Study: 15704689
Drug: Vardenafil, a
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vardenafil, a phosphodiesterase 5 inhibitor; dosage and duration not specified.
Study: 12015188
Drug: Telmisartan 40
Normalized name: telmisartan 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telmisartan 40 mg (titrated to 80 mg after 4 weeks)
Study: 12015188
Drug: Enalapril 10
Normalized name: enalapril 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril 10 mg (titrated to 20 mg after 4 weeks)
Study: 12015188
Drug: Telmisartan 40
Normalized name: telmisartan 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telmisartan 40 mg / Enalapril 10 mg
Study: 10369630
Drug: Alternate-day omeprazole
Normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alternate-day omeprazole therapy
Study: 10369630
Drug: On-demand therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: On-demand therapy with omeprazole
Study: 7594361
Drug: Ease of
Normalized name: BOIL-EASE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ease of administration of BMSE
Study: 389354
Drug: Clotrimazole (local
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clotrimazole (local treatment for 6 days)
Study: 389354
Drug: Clotrimazole (local
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clotrimazole (local treatment for 6 days) + Nystatin (oral treatment for 10 days)
Study: 25801708
Drug: EADB-100 (Quadruple
Approvals — FDA: no, EMA: no, PMDA: no
Description: EADB-100 (Quadruple therapy with esomeprazole, amoxicillin, DOX-100 mg b.i.d., and bismuth subcitrate)
Study: 25801708
Drug: EADB-200 (Quadruple
Approvals — FDA: no, EMA: no, PMDA: no
Description: EADB-200 (Quadruple therapy with esomeprazole, amoxicillin, DOX-200 mg b.i.d., and bismuth subcitrate)
Study: 23600548
Drug: 300IR 5-grass
Normalized name: Buffalo grass
DrugBank: Anthoxanthum odoratum (DB14163)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300IR 5-grass pollen sublingual tablet (4M group)
Study: 23600548
Drug: 300IR 5-grass
Normalized name: Buffalo grass
DrugBank: Anthoxanthum odoratum (DB14163)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300IR 5-grass pollen sublingual tablet (2M group)
Study: 12641501
Drug: Conventional 13C-UBT
Normalized name: 13C-urea
DrugBank: Urea C-13 (DB09510)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Conventional 13C-UBT (75 mg 13C-urea)
Study: 12641501
Drug: Tablet-based 13C-UBT
Normalized name: 13C-urea
DrugBank: Urea C-13 (DB09510)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Tablet-based 13C-UBT (100 mg 13C-urea)
Study: 12641501
Drug: Tablet-based 13C-UBT
Normalized name: 13C-urea
DrugBank: Urea C-13 (DB09510)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Tablet-based 13C-UBT (50 mg 13C-urea)
Study: 12641501
Drug: Conventional 13C-UBT
Normalized name: 13C-urea
DrugBank: Urea C-13 (DB09510)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Conventional 13C-UBT (75 mg 13C-urea) at follow-up
Study: 12641501
Drug: Tablet-based 13C-UBT
Normalized name: 13C-urea
DrugBank: Urea C-13 (DB09510)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Tablet-based 13C-UBT (100 mg 13C-urea) at follow-up
Study: 12641501
Drug: Tablet-based 13C-UBT
Normalized name: 13C-urea
DrugBank: Urea C-13 (DB09510)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Tablet-based 13C-UBT (50 mg 13C-urea) at follow-up
Study: 8478759
Drug: Midazolam (0.35
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam (0.35 mg/kg)
Study: 8478759
Drug: Diazepam (0.70
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diazepam (0.70 mg/kg)
Study: 3094356
Drug: Sustained-release nitroglycerin,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustained-release nitroglycerin, 13 mg
Study: 3094356
Drug: Diltiazem, 60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diltiazem, 60 mg
Study: 26945843
Drug: IL-1 receptor
Normalized name: IL-1 TRAP
DrugBank: Rilonacept (DB06372)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IL-1 receptor antagonist (IL-1Ra)
Study: 23335852
Drug: Calcium dobesilate
Normalized name: CALCIUM DOBESILATE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium dobesilate (CaD) 500 mg daily for 3 months
Study: 20358358
Drug: 4 mg
Normalized name: lutein 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg IV zoledronic acid
Study: 16636210
Drug: Warfarin sodium
Normalized name: Warfarin Sodium
DrugBank: Warfarin (DB00682)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Warfarin sodium (target international normalized ratio, 2.0‐3.0)
Study: 11226087
Drug: RSR13 (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: RSR13 (75 mg/kg and 100 mg/kg doses)
Study: 11226087
Drug: RSR13 (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: RSR13 (all doses)
Study: 3258222
Drug: Acute normovolemic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acute normovolemic hemodilution (10 ml/kg; n = 15) using hydroxyethyl starch solution (HES)
Study: 25778112
Drug: Concurrent presence
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent presence of low VM area, high VM %Fat, and high BMI
Study: 23177418
Drug: Split-dose group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Split-dose group (75 IU rHLH given as four equally divided doses)
Study: 23177418
Drug: Single-dose group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-dose group (75 IU rHLH given as a single dose)
Study: 23177418
Drug: Split-dose group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Split-dose group
Study: 19657112
Drug: Higher plasma
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher plasma levels of sex hormone-binding globulin (SHBG)
Study: 19657112
Drug: Increase in
Normalized name: Incruse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Increase in plasma level of sex hormone-binding globulin (SHBG)
Study: 16920503
Drug: Preoperative recombinant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preoperative recombinant human GM-CSF (rhGM-CSF) administration
Study: 11383355
Drug: 2 implants
Normalized name: Drug Implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 implants with ball attachment
Study: 11383355
Drug: 2 implants
Normalized name: Drug Implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 implants interconnected with a bar
Study: 11383355
Drug: 4 implants
Normalized name: Drug Implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 implants interconnected with bars
Study: 8996264
Drug: 5-fluorouracil/epinephrine injectable
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-fluorouracil/epinephrine injectable gel (5-FU/epi gel)
Study: 8996264
Drug: 5-fluorouracil/epinephrine injectable
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-fluorouracil/epinephrine injectable gel (5-FU/epi gel) at a dose of 0.5 ml three times a week for 2 weeks
Study: 30477846
Drug: Disease-specific suggestions
Normalized name: Pacific halibut
DrugBank: Pacific halibut (DB10616)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Disease-specific suggestions (using counter-hyperarousal hypnotic exercise and screen visualization technique)
Study: 25909533
Drug: Implant-connected partial
Normalized name: rosin partially dimerized glycerol ester
Approvals — FDA: no, EMA: no, PMDA: no
Description: Implant-connected partial dentures
Study: 16622463
Drug: Dose-dense chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose-dense chemotherapy (DD) with epirubicin 90 mg/m² plus paclitaxel 175 mg/m² in four 14-day cycles, followed by CMF 600/40/600 in three 14-day cycles, plus filgrastim 5 µg/kg/day
Study: 16622463
Drug: Conventional-schedule chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional-schedule chemotherapy (CS) with epirubicin 90 mg/m² plus cyclophosphamide 600 mg/m² in four 21-day cycles, followed by CMF 600/40/600 in three 21-day cycles, plus filgrastim if required
Study: 10195613
Drug: Yellow fever
Normalized name: yellow fever live
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yellow fever vaccine administered 1-6 days after measles vaccination
Study: 10195613
Drug: Yellow fever
Normalized name: yellow fever live
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yellow fever vaccine administered 7-13 days after measles vaccination
Study: 10195613
Drug: Yellow fever
Normalized name: yellow fever live
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yellow fever vaccine administered 14-21 days after measles vaccination
Study: 10195613
Drug: Yellow fever
Normalized name: yellow fever live
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yellow fever vaccine administered 22-27 days after measles vaccination
Study: 10195613
Drug: Yellow fever
Normalized name: yellow fever live
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yellow fever vaccine administered >28 days after measles vaccination
Study: 1962905
Drug: Low molecular
Normalized name: Low molecular weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low molecular weight heparin (FR‐860)
Study: 1962905
Drug: Unfractionated heparin
Normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Unfractionated heparin (H‐25)
Study: 1962905
Drug: Low molecular
Normalized name: Low molecular weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low molecular weight heparin (F‐50)
Study: 1962905
Drug: Low molecular
Normalized name: Low molecular weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low molecular weight heparin (F‐25 and F‐35)
Study: 29625777
Drug: Pulmonary Rehabilitation
Normalized name: Lobaria pulmonaria extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pulmonary Rehabilitation (PR) thrice weekly for 12 weeks
Study: 29625777
Drug: Tai Chi
Normalized name: Ma Chi Xian
DrugBank: Purslane (DB14327)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tai Chi five times weekly for 12 weeks
Study: 26302142
Drug: 6-month pharmacist
Normalized name: leuprolide
DrugBank: Leuprolide (DB00007)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6-month pharmacist intervention comprising collaborative care, medication review, and tailored adherence counseling including motivational interviewing and telephone follow-ups.
Study: 23208945
Drug: Classification-based cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Classification-based cognitive functional therapy
Study: 18192510
Drug: High-dose senicapoc
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose senicapoc (10 mg/day)
Study: 10568568
Drug: Nitric-oxide-generating gel
Normalized name: Nitric Oxide
DrugBank: Nitric Oxide (DB00435)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nitric-oxide-generating gel
Study: 10568568
Drug: Placebo gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo gel (KY jelly only)
Study: 7061569
Drug: Patients after
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients after chemotherapy
Study: 30835326
Drug: Non-RA treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-RA treatment
Study: 29089056
Drug: Lotilaner (20-43
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lotilaner (20-43 mg/kg)
Study: 26227783
Drug: 800 mg
Normalized name: bran 800 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 800 mg synthetic GABA
Study: 26227783
Drug: 800 mg
Normalized name: bran 800 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 800 mg oral microcrystalline cellulose (placebo)
Study: 23038750
Drug: Polypill strategy
Normalized name: POLYPILUS FRONDOSUS WHOLE
DrugBank: Grifola frondosa whole (DB19262)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polypill strategy (combining aspirin, a statin, and two blood pressure lowering agents)
Study: 20137476
Drug: Low-dose amiodarone
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose amiodarone (10 mg/kg daily for 7 days before surgery and 200 mg daily for 10 days postoperatively)
Study: 9833596
Drug: Racemic propafenone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Racemic propafenone (150 mg every 6 h)
Study: 9833596
Drug: (S)‐propafenone (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: (S)‐propafenone (150 mg every 6 h)
Study: 9833596
Drug: (R)‐propafenone (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: (R)‐propafenone (150 mg every 6 h)
Study: 8589464
Drug: Patient age,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient age, use of calcium channel blockers, presence of diabetes mellitus (DM)
Study: 2666363
Drug: Initial local
Normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Initial local control with radiation therapy or radiation plus surgery
Study: 2666363
Drug: Salvage therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salvage therapy for metastatic disease
Study: 793437
Drug: Human leukocyte
Normalized name: Human leukocyte antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Human leukocyte interferon (HLI) 3 X 10(‐6) units/ml, two drops twice daily
Study: 30700356
Drug: Trastuzumab with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trastuzumab with neoadjuvant chemotherapy (n=89, n=64 received complete standard dose)
Study: 30700356
Drug: Neoadjuvant chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant chemotherapy only (Control group, n=67)
Study: 19176440
Drug: N-terminal BNP-guided
Normalized name: N-ethylurea
Approvals — FDA: no, EMA: no, PMDA: no
Description: N-terminal BNP-guided therapy
Study: 12754730
Drug: Psychotic group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psychotic group nurses (read vignette with patient on haloperidol, benztropine, lorazepam, trazadone, fluoxetine, and lithium)
Study: 12754730
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group nurses (read vignette without psychiatric medication)
Study: 9369825
Drug: Subcutaneous terbutaline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous terbutaline sulfate (0.25 mg)
Study: 24773760
Drug: Motivational interviewing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Motivational interviewing (MIG) plus standard care (information sheet on glaucoma and its treatment)
Study: 22466942
Drug: Auricular therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Auricular therapy combined with optimized Yinxieling Formula
Study: 15951736
Drug: PTNS performed
Normalized name: Perform
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PTNS performed weekly (Group A)
Study: 10600247
Drug: Alcohol (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alcohol (single dose)
Study: 2220647
Drug: Nonpharmacologic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonpharmacologic therapy combined with one of five active drug regimens (acebutolol, amlodipine, chlorthalidone, doxazosin, enalapril)
Study: 2220647
Drug: Nonpharmacologic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonpharmacologic treatment only
Study: 93353
Drug: Lithium carbonate
Normalized name: Lithium Carbonate
DrugBank: Lithium carbonate (DB14509)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lithium carbonate (1.0 up to 1.5 g/day)
Study: 93353
Drug: Metizol (thiamazol)
Normalized name: amitriptyline hydrochloride Extended Release Oral Capsule [Lentizol]
DrugBank: Methimazole (DB00763)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metizol (thiamazol) 60 mg/day
Study: 93353
Drug: Combined therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined therapy with lithium and metizol
Study: 23241439
Drug: Drug Free
Normalized name: Tenscare Pain Aide Drug Free Pain Relief
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug Free Interval Strategy (DFIS)